Fan Zhou's picture

Fan Zhou

  • E-mailfan.zhou@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2024). Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection. npj Vaccines. 9 pages.
  • Show author(s) (2023). Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. iScience. 18 pages.
  • Show author(s) (2023). SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients. Frontiers in Immunology. 11 pages.
  • Show author(s) (2023). Prolonging the delivery of influenza virus vaccine improves the quantity and quality of the induced immune responses in mice. Frontiers in Immunology.
  • Show author(s) (2023). Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study. Frontiers in Immunology. 16 pages.
  • Show author(s) (2023). Dynamics of circulating lymphocytes responding to human experimental enterotoxigenic Escherichia coli infection. European Journal of Immunology.
  • Show author(s) (2023). Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. Vaccine: X. 1-11.
  • Show author(s) (2022). Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study. Frontiers in Immunology. 17 pages.
  • Show author(s) (2022). Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. npj Vaccines. 11 pages.
  • Show author(s) (2022). The evolution of humoral immune responses to past and novel influenza virus strains gives evidence for antigenic seniority. Frontiers in Immunology. 1-15.
  • Show author(s) (2022). Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. Clinical Infectious Diseases.
  • Show author(s) (2022). Persistent Fever and Positive PCR 90 Days Post-SARS-CoV-2 Infection in a Rituximab-Treated Patient: A Case of Late Antiviral Treatment. Viruses.
  • Show author(s) (2022). Human organotypic airway and lung organoid cells of bronchiolar and alveolar differentiation are permissive to infection by influenza and SARS-CoV-2 respiratory virus. Frontiers in Cellular and Infection Microbiology. 1-23.
  • Show author(s) (2022). Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients. PLOS ONE. 16 pages.
  • Show author(s) (2022). A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine. 11 pages.
  • Show author(s) (2022). A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease. International Journal of Molecular Sciences.
  • Show author(s) (2021). Repeated Influenza Vaccination Boosts and Maintains H1N1pdm09 Neuraminidase Antibody Titers. Frontiers in Immunology. 1-11.
  • Show author(s) (2021). Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection. Frontiers in Immunology. 1-13.
  • Show author(s) (2021). Long COVID in a prospective cohort of home-isolated patients. Nature Medicine. 1607-1613.
  • Show author(s) (2021). Functional and Binding H1N1pdm09-Specific Antibody Responses in Occasionally and Repeatedly Vaccinated Healthcare Workers: A Five-Year Study (2009-2014). Frontiers in Immunology.
  • Show author(s) (2021). Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. The Lancet Regional Health - Europe. 9 pages.
  • Show author(s) (2020). SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. Journal of Infectious Diseases.
  • Show author(s) (2020). Live-attenuated influenza vaccine induces tonsillar follicular T helper cell responses that correlate with antibody induction. Journal of Infectious Diseases. 21-32.
  • Show author(s) (2020). Development and assessment of a pooled serum as candidate standard to measure influenza a virus group 1 hemagglutinin stalk-reactive antibodies. Vaccines. 1-18.
  • Show author(s) (2019). No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination. Vaccine: X. 1-8.
  • Show author(s) (2019). Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination. Scandinavian Journal of Immunology. 1-12.
  • Show author(s) (2018). T follicular-like helper cells in the peripheral blood of patients with primary Sj√∂gren's syndrome. Scandinavian Journal of Immunology. 1-15.
  • Show author(s) (2018). Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years. npj Vaccines. 10 pages.
  • Show author(s) (2018). Antibody responses to influenza A/H1N1pdm09 virus after pandemic and seasonal influenza vaccination in healthcare workers: A 5-year follow-up study. Clinical Infectious Diseases. 382-392.
  • Show author(s) (2017). Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination. Vaccine. 5666-5673.
  • Show author(s) (2017). Boosting of cross-reactive and protection-associated T cells in children after live attenuated influenza vaccination. Journal of Infectious Diseases. 1527-1535.
  • Show author(s) (2017). A DNA vaccine that targets hemagglutinin to antigen-presenting cells protects mice against H7 influenza. Journal of Virology. 1-13.
  • Show author(s) (2016). Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-cell responses following repeated annual influenza vaccination. Journal of Infectious Diseases. 740-749.
  • Show author(s) (2015). Single dose vaccination of the ASO3-adjuvanted A (H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Human Vaccines & Immunotherapeutics. 1654-1662.
  • Show author(s) (2015). Induction of local secretory IgA and multifunctional CD4+ T-helper cells following intranasal immunization with a H5N1 whole inactivated influenza virus vaccine in BALB/c mice. Scandinavian Journal of Immunology. 305-317.
Academic lecture
  • Show author(s) (2019). Comprehensive characterization and kinetics of circulating lymphocytes in human volunteers experimentally infected with enterotoxigenic Escherichia coli.
  • Show author(s) (2015). Cellular immune responses after live attenuated influenza vaccination in children, a clinical trial.
Letter to the editor
  • Show author(s) (2023). SARS-CoV-2 infection induces long-lived B and T-cell responses up to 15 months post-infection, irrespective of disease severity. Journal of Infection. 346-349.
  • Show author(s) (2019). Neuraminidase antibody responses after pandemic and seasonal influenza vaccinations: a five-year study.
  • Show author(s) (2019). Neuraminidase Antibody Responses After Pandemic And Seasonal Vaccination: A Five-Year Study.
  • Show author(s) (2018). Comprehensive characterization of circulating T follicular helper cells and plasmablasts in human volunteers experimentally infected with enterotoxigenic Escherichia coli.
  • Show author(s) (2023). Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants (npj Vaccines, (2022), 7, 1, (174), 10.1038/s41541-022-00586-7). npj Vaccines.
  • Show author(s) (2018). Publisher Correction: Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years. npj Vaccines.
Academic literature review
  • Show author(s) (2018). Improving influenza vaccines: challenges to effective implementation. Current Opinion in Immunology. 88-95.
  • Show author(s) (2018). Clinical expectations for better influenza virus vaccines - perspectives from the young investigators' point of view. Vaccines. 1-16.

More information in national current research information system (CRIStin)

Fields of competence